Traws Pharma Inc Asset Resilience Ratio
Traws Pharma Inc asset resilience ratio. Traws Pharma Inc (TRAW) has an Asset Resilience Ratio of 24.09% as of September 2014. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Traws Pharma Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Traws Pharma Inc (2013–2013)
Asset resilience ratio of Traws Pharma Inc from 2013 to 2013. This chart shows how Traws Pharma Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Traws Pharma Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Traws Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Traws Pharma Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $15.00 Million | 24.09% |
| Total Liquid Assets | $15.00 Million | 24.09% |
Asset Resilience Insights
- Good Liquidity Position: Traws Pharma Inc maintains a healthy 24.09% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Traws Pharma Inc Industry Peers by Asset Resilience Ratio
Compare Traws Pharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Traws Pharma Inc Asset Resilience Ratio by Year (2013–2013)
Traws Pharma Inc asset resilience ratio by year from 2013 to 2013. The table below shows the annual Asset Resilience Ratio data for Traws Pharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2013-12-31 | 38.03% | $39.99 Million | $105.15 Million | -- |
About Traws Pharma Inc
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonu… Read more